Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center
• Collaborator: Roche Pharma AG
• Treatments: Capecitabine; Gemcitabine

Criteria

Inclusion Criteria:

• Metastatic or unresectable pancreatic cancer

• No prior chemotherapy except radiation-sensitizing doses of 5-FU

• No radiotherapy less than 4 weeks prior to the start of the study

Exclusion Criteria:

• Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-FU

• Moderate to severe renal impairment

• Uncontrolled diabetes

• Inability to swallow tablets